ChemoCentryx Company Profile (NASDAQ:CCXI)

About ChemoCentryx

ChemoCentryx logoChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CCXI
  • CUSIP: 16383L10
Key Metrics:
  • Previous Close: $7.17
  • 50 Day Moving Average: $7.34
  • 200 Day Moving Average: $6.55
  • 52-Week Range: $1.92 - $9.10
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.06
  • P/E Growth: 0.00
  • Market Cap: $313.12M
  • Outstanding Shares: 47,805,000
  • Beta: 1.52
Profitability:
  • Return on Equity: -71.28%
  • Return on Assets: -41.63%
Debt:
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Additional Links:
Companies Related to ChemoCentryx:

Analyst Ratings

Consensus Ratings for ChemoCentryx (NASDAQ:CCXI) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $11.00 (67.94% upside)

Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017JMP SecuritiesInitiated CoverageMkt Outperform -> OutperformView Rating Details
8/9/2016J P Morgan Chase & CoReiterated RatingBuy$11.00View Rating Details
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for ChemoCentryx (NASDAQ:CCXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details
11/5/2014($0.28)($0.25)ViewN/AView Earnings Details
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details
3/13/2014($0.25)($0.22)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-1.08 EPS

Dividends

Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for ChemoCentryx (NASDAQ:CCXI)
Insider Ownership Percentage: 26.80%
Institutional Ownership Percentage: 48.16%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/3/2017Markus J CappelInsiderSell26,821$7.51$201,425.71View SEC Filing  
12/16/2016Petrus BekkerInsiderSell8,712$8.74$76,142.88View SEC Filing  
12/5/2016Petrus BekkerInsiderSell30,000$8.50$255,000.00View SEC Filing  
11/22/2016Petrus BekkerInsiderSell1,250$8.30$10,375.00View SEC Filing  
11/11/2016Petrus BekkerInsiderSell33,332$8.00$266,656.00View SEC Filing  
9/1/2016Roger C LucasDirectorSell4,000$5.07$20,280.00View SEC Filing  
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.16View SEC Filing  
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.00View SEC Filing  
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.00View SEC Filing  
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.00View SEC Filing  
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.00View SEC Filing  
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.00View SEC Filing  
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ChemoCentryx (NASDAQ:CCXI)
DateHeadline
marketexclusive.com logoAnalyst Activity – JMP Securities Initiates Coverage On ChemoCentryx (NASDAQ:CCXI) With a Mkt Outperform (NASDAQ:CCXI)
marketexclusive.com - February 22 at 12:13 PM
finance.yahoo.com logoCoverage initiated on ChemoCentryx by JMP Securities (NASDAQ:CCXI)
finance.yahoo.com - February 22 at 12:13 PM
marketexclusive.com logoAnalyst Activity – JMP Securities Initiates Coverage On ChemoCentryx (NASDAQ:CCXI) With a Outperform - Market Exclusive (NASDAQ:CCXI)
marketexclusive.com - February 21 at 2:10 PM
News IconAnalyst Target Price & Stock Review on ChemoCentryx, Inc. (NASDAQ:CCXI) Aduro BioTech, Inc. (NASDAQ:ADRO) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - February 19 at 3:57 PM
News IconShares in Focus: ChemoCentryx, Inc. (NASDAQ:CCXI) - Piedmont Register (NASDAQ:CCXI)
piedmontregister.com - February 18 at 8:48 AM
News IconShares in View: ChemoCentryx Inc. (CCXI) - Benton Bulletin (NASDAQ:CCXI)
bentonbulletin.com - February 18 at 8:48 AM
News IconReviewing the Levels for ChemoCentryx, Inc. (NASDAQ:CCXI) - BVN (NASDAQ:CCXI)
bvnewsjournal.com - February 18 at 8:48 AM
News IconPrice Index Watch on Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) - Searcy News (NASDAQ:CCXI)
searcysentinel.com - February 17 at 3:34 PM
News IconChart Watch: Following Indicators on Shares of ChemoCentryx Inc. (CCXI) - The Standard (NASDAQ:CCXI)
6milestandard.com - February 16 at 9:02 AM
globenewswire.com logoVifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases (NASDAQ:CCXI)
globenewswire.com - February 14 at 2:53 AM
News IconBig Banks Continue to be Large Stakeholders in ChemoCentryx, Inc. (NASDAQ:CCXI) - Midway Monitor (NASDAQ:CCXI)
midwaymonitor.com - February 8 at 4:30 PM
News IconHow Often Does ChemoCentryx, Inc. (NASDAQ:CCXI) Miss ... - Post Analyst (NASDAQ:CCXI)
postanalyst.com - February 7 at 2:18 AM
News IconTechnical Toolbox: Investor Focus on ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - February 3 at 4:25 PM
News IconLooking at Moving Averages for ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - February 2 at 9:34 PM
News IconMarket Check: Narrowing in on Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) - The Tribune (NASDAQ:CCXI)
lakecitytribune.com - January 30 at 9:58 PM
News IconCalibrating the Trade: Watching Technicals on Shares of ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - January 30 at 9:58 PM
News IconLooking at the Gauges on ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - January 27 at 5:34 PM
News IconWhat Are the Technicals Saying About These Shares: ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - January 26 at 10:05 PM
News IconShares in View: ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - January 25 at 5:18 PM
streetinsider.com logoChemoCentryx (CCXI) Announces Presentation of Data from ... - StreetInsider.com (NASDAQ:CCXI)
www.streetinsider.com - January 21 at 9:16 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: ChemoCentryx, Inc. (NASDAQ:CCXI) - Wall Street Beacon (NASDAQ:CCXI)
wsbeacon.com - January 21 at 9:16 PM
nasdaq.com logoChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq ... - Nasdaq (NASDAQ:CCXI)
www.nasdaq.com - January 21 at 9:16 PM
nasdaq.com logoChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor (NASDAQ:CCXI)
www.nasdaq.com - January 20 at 10:20 PM
streetinsider.com logoChemoCentryx (CCXI) Announces Presentation of Data from Ongoing Phase Ib Trial of CCR2 Inhibitor CCX872 at ASCO (NASDAQ:CCXI)
www.streetinsider.com - January 20 at 5:20 PM
4-traders.com logoChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical .. (NASDAQ:CCXI)
www.4-traders.com - January 20 at 5:20 PM
us.rd.yahoo.com logoChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco (NASDAQ:CCXI)
us.rd.yahoo.com - January 20 at 5:20 PM
us.rd.yahoo.com logoChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer (NASDAQ:CCXI)
us.rd.yahoo.com - January 20 at 5:20 PM
us.rd.yahoo.com logo3:34 pm ChemoCentryx presents from a continuing open-label, single-arm Phase Ib clinical trial of CCX872 at ASCO 2017; plans to further investigate CCX872 in combination with a checkpoint inhibitor. (NASDAQ:CCXI)
us.rd.yahoo.com - January 20 at 5:20 PM
feeds.reuters.com logoBRIEF-ChemoCentryx says its drug CCX872 well tolerated in clinical trial (NASDAQ:CCXI)
feeds.reuters.com - January 20 at 4:12 PM
News IconWhat are the Levels Indicating for This Stock: ChemoCentryx Inc. (CCXI) - Sherwood Daily (NASDAQ:CCXI)
sherwooddaily.com - January 19 at 10:27 PM
capitalcube.com logoChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19, 2017 (NASDAQ:CCXI)
www.capitalcube.com - January 19 at 5:24 PM
streetinsider.com logoChemoCentryx (CCXI) Offers Update, Development Strategy (NASDAQ:CCXI)
www.streetinsider.com - January 9 at 5:21 PM
finance.yahoo.com logoChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases (NASDAQ:CCXI)
finance.yahoo.com - January 9 at 5:20 PM
marketexclusive.com logoInsider Trading Activity ChemoCentryx, Inc. (NASDAQ:CCXI) – Insider Sold 26821 shares of Stock - Market Exclusive (NASDAQ:CCXI)
marketexclusive.com - January 7 at 3:23 AM
News IconChemoCentryx Inc CCXI Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CCXI)
www.bioportfolio.com - January 6 at 4:36 PM
finance.yahoo.com logoChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:CCXI)
finance.yahoo.com - January 4 at 5:13 PM
capitalcube.com logoChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : January 3, 2017 (NASDAQ:CCXI)
www.capitalcube.com - January 3 at 11:31 AM
capitalcube.com logoChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2, 2017 (NASDAQ:CCXI)
www.capitalcube.com - January 2 at 4:32 PM
News IconBay Area Biotech Nabs $50 Million Cash Upfront in Partnership Expansion With Vifor Pharma (NASDAQ:CCXI)
www.biospace.com - December 27 at 12:26 PM
investingnews.com logoVifor Pharma and Chemocentryx Announce Expansion of Kidney Health Alliance to Include CCX140 (NASDAQ:CCXI)
investingnews.com - December 23 at 9:26 PM
4-traders.com logoCHEMOCENTRYX, INC. (NASDAQ:CCXI) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:CCXI)
www.4-traders.com - December 23 at 9:26 PM
streetinsider.com logoVifor Pharma, ChemoCentryx (CCXI) Expand Pact to Include CCX140 to Treat Renal Diseases - StreetInsider.com (NASDAQ:CCXI)
www.streetinsider.com - December 23 at 2:24 AM
publicnow.com logoVifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseases01 (NASDAQ:CCXI)
www.publicnow.com - December 23 at 2:24 AM
streetinsider.com logoVifor Pharma, ChemoCentryx (CCXI) Expand Pact to Include CCX140 to Treat Renal Diseases (NASDAQ:CCXI)
www.streetinsider.com - December 22 at 4:20 PM
finance.yahoo.com logo12:30 pm ChemoCentryx and Vifor Pharma expand existing health alliance to include the development and commercialization of CCX140 for renal diseases; co to receive upfront cash commitment of $50 mln --shares halted-- (NASDAQ:CCXI)
finance.yahoo.com - December 22 at 4:20 PM
finance.yahoo.com logoVifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases (NASDAQ:CCXI)
finance.yahoo.com - December 22 at 4:20 PM
biz.yahoo.com logoCHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:CCXI)
biz.yahoo.com - December 22 at 4:20 PM
feeds.benzinga.com logoChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases (NASDAQ:CCXI)
feeds.benzinga.com - December 22 at 3:22 PM
News IconStock Spotlight: Checking on Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) - OIB News (NASDAQ:CCXI)
oibnews.com - December 20 at 6:46 AM
News IconTrading Views: Checking the Numbers for ChemoCentryx Inc. (CCXI) - Yankee Analysts (NASDAQ:CCXI)
yankeeanalysts.com - December 20 at 6:46 AM

Social

What is ChemoCentryx's stock symbol?

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

Where is ChemoCentryx's stock going? Where will ChemoCentryx's stock price be in 2017?

3 brokers have issued 12 month target prices for ChemoCentryx's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate ChemoCentryx's stock price to reach $11.00 in the next year.

When will ChemoCentryx announce their earnings?

ChemoCentryx is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about ChemoCentryx stock?

Here are some recent quotes from research analysts about ChemoCentryx stock:

  • According to Zacks Investment Research, "ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. " (1/17/2017)

  • J P Morgan Chase & Co analysts commented, "ChemoCentryx announced a GAAP loss per share of $0.22. Overall, highlights on the call were incremental and the company continues to make steady progress across key programs. Of note, related to CCX168 in ANCA-associated vasculitis (AAV), the company has had initial discussions with US / EU regulatory bodies. Along with the recent strategic partnering with Vifor Pharma, we believe that the potential advancement of CCX168 into phase 3 would provide further validation to the phase 2 datasets (phase 3 program expected to start by YE16; see our thoughts from CLEAR and CLASSIC studies here and here). Looking forward beyond CCX168 in AAV, there are additional catalysts worth monitoring, including early data from CCX168 in aHUS (late-2016; potentially ASN in November) and ORR (3Q) / initial PFS (4Q) data for CCX872." (8/9/2016)

  • Cowen and Company analysts commented, "Chemocentryx’s Investor Meeting offered a review of lead candidates CCX168 for." (5/19/2016)

Who owns ChemoCentryx stock?

ChemoCentryx's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.46%), Renaissance Technologies LLC (0.98%), State Street Corp (0.84%), Oxford Asset Management (0.59%), City Financial Investment Co Ltd (0.31%) and Bogle Investment Management L P DE (0.22%). Company insiders that own ChemoCentryx stock include Bvf Partners L P/Il, Geoffrey M Parker, Ira Klein, James L Tyree, Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya, Thomas A Edwards, Thomas J Schall and Value Fund L P Biotechnology.

Who sold ChemoCentryx stock? Who is selling ChemoCentryx stock?

ChemoCentryx's stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management, Franklin Resources Inc., Keybank National Association OH and State Street Corp. Company insiders that have sold ChemoCentryx stock in the last year include James L Tyree, Markus J Cappel, Petrus Bekker and Roger C Lucas.

Who bought ChemoCentryx stock? Who is buying ChemoCentryx stock?

ChemoCentryx's stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, City Financial Investment Co Ltd, Federated Investors Inc. PA, Russell Investments Group Ltd. and Bogle Investment Management L P DE. Company insiders that have bought ChemoCentryx stock in the last two years include Geoffrey M Parker and Thomas A Edwards.

How do I buy ChemoCentryx stock?

Shares of ChemoCentryx can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ChemoCentryx stock cost?

One share of ChemoCentryx stock can currently be purchased for approximately $6.55.

ChemoCentryx (NASDAQ:CCXI) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Earnings History Chart

Earnings by Quarter for ChemoCentryx (NASDAQ:CCXI)

Dividend History Chart

Dividend Payments by Quarter for ChemoCentryx (NASDAQ:CCXI)

Last Updated on 2/23/2017 by MarketBeat.com Staff